Search results
Showing 1201 to 1215 of 8314 results
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
NICE is unable to make a recommendation on cemiplimab (Libtayo) for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. This is because Sanofi did not provide an evidence submission.
Show all sections
Sections for TA848
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)
Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention for treating acute coronary syndromes in adults.
Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures in adults.
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)
NICE is unable to recommend the use in the NHS of decitabine for acute myeloid leukaemia. This is because Janssen did not provide an evidence submission.
Show all sections
Sections for TA270
NICE is unable to recommend the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia. This is because Lilly did not provide an evidence submission
Show all sections
Sections for TA273
NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care. his is because TMC Pharma Services did not provide an evidence submission.
Show all sections
Sections for TA277
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.